Table 4.
Pharmacokinetic Parameters of REG After Oral Administration of Controls and T80-STA Niosomes to Rats (n=6, Mean ± SD)
| Formulation | T max (hours) | C max (ng/mL) | AUC0→∞ (ng⋅h/mL) | MRT (hours) | FRa (%) |
|---|---|---|---|---|---|
|
Suspension (Susp) |
0.5 ± 0.0 | 354.2 ± 26.3 | 1384 ± 266 | 3.8 ± 0.3 | |
| T80 | 0.8 ± 0.1*** | 1414.0 ± 247.3*** | 3832 ± 505*** | 6.1 ± 0.2*** | 2.77 |
| T80-STA | 0.5 ± 0.0 | 1676.0 ± 257.4*** | 5193 ± 500*** | 4.7 ± 0.7* | 3.75 |
| Empty T80-STA+ Susp | 0.5 ± 0.0 | 1364.2 ± 108.0*** | 3893 ± 207*** | 3.8 ± 0.2 | 2.81 |
Notes: aFR, the relative bioavailability (%) of repaglinide calculated based on the AUC0→∞ of the drug suspension as the reference. *p < 0.05 and ***p < 0.001 significant difference compared with the suspension of REG.
Abbreviations: AUC, area under the drug concentration–time curve; MRT, mean residence time.